AFFÄRSIDÉ

Ziccums affärsidé är att utveckla nya beredningar av biologiska läkemedel genom bolagets patenterade teknologi LaminarPace, som utvecklar torra beredningsformer av produkter som i nuläget enbart finns i vätskeform.

Bransch: Sjukvård
Marknad: First North Stockholm
Tickerkod: ZICC
Certified Adviser: Erik Penser Bank

WEBBPLATS

OMSÄTTNING OCH AKTIEKURS

I grafen visas aktiekursutveckling och omsättning för valt bolag. Informationen är fördröjd med 15 min.

Omsättning
Aktuell Kurs
Utvecklingen i dag
Analyser | 27 Jan 2023 | Ziccum

ZICCUM AB (publ) Year-end report Q4 2022…

YEAR-END REPORT Q4 2022: 1 JANUARY – 31 DECEMBER 2022 To read the digital Report, please click here: https://reports-en.ziccum.com/year-end-report-q4-2022/start/   Significant events in Q4 (October – December) On October 24,…

Läs hela nyheten
Analyser | 23 Jan 2023 | Ziccum

Ziccum submits Expression of Interest…

Ziccum AB (publ) (‘Ziccum’) has now submitted its Expression of Interest application for CEPI’s Call for Proposals for funding of innovations that improve vaccine thermostability. The Coalition for Epidemic Preparedness…

Läs hela nyheten
Analyser | 18 Jan 2023 | Ziccum

Ziccum CEO to present at international…

Lund, Jan 18, 2023 —Ziccum AB CEO Ann Gidner will present LaminarPace, the company’s unique mass transfer drying methodology, at the mRNA-based Therapeutics Summit in Berlin 24 – 26 January.…

Läs hela nyheten
Analyser | 16 Dec 2022 | Ziccum

Ziccum awarded 10 MSEK Eurostars funding…

Ziccum AB has been awarded non-dilutive funding of 10 MSEK by Eurostars for a joint application with the Institute of Computational Physics (ICP) at the School of Engineering at Zurich…

Läs hela nyheten
Analyser | 14 Dec 2022 | Ziccum

Ziccum launches new, expanded website

Lund, Nov 14, 2022 —Ziccum AB (publ) (‘Ziccum’) has launched a new website, developed in partnership with the Chords Agency in Malmö. With a new brand platform, the expanded site…

Läs hela nyheten
Analyser | 8 Dec 2022 | Ziccum

Ziccum signs agreement with Zurich…

Ziccum AB has signed an agreement contracting the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’ School of Engineering (ZHAW) for the next phase of the…

Läs hela nyheten
Analyser | 28 Oct 2022 | Ziccum

Ziccums Q3-resultat: VD-uppdatering på…

Ziccum har haft ett mycket produktivt kvartal, med avsevärda framsteg inom de tre fokusområdena: Partnering, Teknologiutveckling och Förstudien för mRA/LNP-plattformen. Ann Gidner, Ziccums nya VD som tillträdde i maj månad…

Läs hela nyheten
Analyser | 27 Oct 2022 | Ziccum

ZICCUM AB (publ) Interim report Q3 2022

INTERIM REPORT Q3 2022: 1 JANUARY – 30 SEPTEMBER 2022. To read the digital Report, please click here: https://reports-en.ziccum.com/interim-report-q3-2022/start/ Significant events during Q3 (July-September) On July 19, Ziccum published the…

Läs hela nyheten
Analyser | 24 Oct 2022 | Ziccum

Ziccum generates proof of successful…

ZICCUM AB (publ) has generated proof of successful nebulization and drying of vaccine lipid nanoparticles (LNP) in its in-house mRNA project. This was carried out using LaminarPaceTM, the company’s ambient…

Läs hela nyheten
Analyser | 27 Sep 2022 | Ziccum

Ziccum reopens application for CEPI…

Ziccum AB (publ) (‘Ziccum’) today announces that is has reopened its application process for CEPI’s Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will…

Läs hela nyheten

Kommande händelser

27 Apr 2023 | Kvartalsrapport 2023-Q1